A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00001056
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : April 30, 2012
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)